SK bioscience Co.,Ltd.

KOSE:A302440 Stock Report

Market Cap: ₩3.7t

SK bioscienceLtd (A302440) Stock Overview

Engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. More details

A302440 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for A302440 from our risk checks.

A302440 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

SK bioscience Co.,Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for SK bioscienceLtd
Historical stock prices
Current Share Price₩47,600.00
52 Week High₩61,500.00
52 Week Low₩35,800.00
Beta1.22
1 Month Change3.82%
3 Month Change23.16%
1 Year Change-11.03%
3 Year Change-66.60%
5 Year Changen/a
Change since IPO-71.83%

Recent News & Updates

Is SK bioscienceLtd (KRX:302440) Using Debt Sensibly?

May 14
Is SK bioscienceLtd (KRX:302440) Using Debt Sensibly?

Recent updates

Is SK bioscienceLtd (KRX:302440) Using Debt Sensibly?

May 14
Is SK bioscienceLtd (KRX:302440) Using Debt Sensibly?

Subdued Growth No Barrier To SK bioscience Co.,Ltd. (KRX:302440) With Shares Advancing 25%

Dec 15
Subdued Growth No Barrier To SK bioscience Co.,Ltd. (KRX:302440) With Shares Advancing 25%

Is SK bioscienceLtd (KRX:302440) A Risky Investment?

Jul 11
Is SK bioscienceLtd (KRX:302440) A Risky Investment?

SK bioscienceLtd's (KRX:302440) Weak Earnings May Only Reveal A Part Of The Whole Picture

Mar 23
SK bioscienceLtd's (KRX:302440) Weak Earnings May Only Reveal A Part Of The Whole Picture

Shareholder Returns

A302440KR BiotechsKR Market
7D-1.8%6.6%0.7%
1Y-11.0%24.7%4.9%

Return vs Industry: A302440 underperformed the KR Biotechs industry which returned 24.7% over the past year.

Return vs Market: A302440 underperformed the KR Market which returned 4.9% over the past year.

Price Volatility

Is A302440's price volatile compared to industry and market?
A302440 volatility
A302440 Average Weekly Movement6.1%
Biotechs Industry Average Movement8.1%
Market Average Movement6.0%
10% most volatile stocks in KR Market12.1%
10% least volatile stocks in KR Market3.0%

Stable Share Price: A302440 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A302440's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2018984Jae-Yong Ahnwww.skbioscience.co.kr

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children.

SK bioscience Co.,Ltd. Fundamentals Summary

How do SK bioscienceLtd's earnings and revenue compare to its market cap?
A302440 fundamental statistics
Market cap₩3.73t
Earnings (TTM)-₩47.63b
Revenue (TTM)₩399.83b
9.3x
P/S Ratio
-78.3x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A302440 income statement (TTM)
Revenue₩399.83b
Cost of Revenue₩349.08b
Gross Profit₩50.75b
Other Expenses₩98.38b
Earnings-₩47.63b

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-607.75
Gross Margin12.69%
Net Profit Margin-11.91%
Debt/Equity Ratio19.4%

How did A302440 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/09 20:43
End of Day Share Price 2025/07/09 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SK bioscience Co.,Ltd. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hyonseok KimCLSA
Sunghwan KimCredit Suisse
null nullCredit Suisse